Phantom Neuro, a company developing minimally invasive neural interfaces for intuitive prosthetic control, today announced that it has received approval to conduct its first-in-human Early Feasibility ...
In the race of innovative drug R&D, whether for antibodies, peptides, or novel binding proteins, the efficiency of early-stage molecule discovery is always the key factor determining project success ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results